OC037—Sleep Quality Of Chronic Benzodiazepine Users In Nursing Homes: A Comparative Study With Non-Users  by Bourgeois, J. et al.
Clinical Therapeutics
e14 Volume 35 Number 8S
in the CEDIA buprenorphine assay should be the object of further 
studies. For MAR patients, more specific methods than CEDIA are 
recommended to omit negative sanctions based on false-positive or 
false-negative results.
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Introduction: Self-empowering patients on oral anticoagulation may 
improve their safety and the outcome of this therapy. The aim of 
this study was to evaluate the effect of an individual, video-assisted, 
1-hour education on patient knowledge and on anticoagulation sta-
bility as an intermediate end point.
Patients (or Materials) and Methods: In a cluster-randomized trial 
in 22 general practices, we investigated 369 patients who were on 
oral anticoagulation with phenprocoumon. In 11 practices, trained 
practice nurses educated the patients individually based on a 20-min-
ute video, a leaflet, and a concluding questionnaire. The education 
lasted three quarters of an hour to an hour. Patients in the 11 control 
practices were handed over the leaflet and otherwise treated as usual. 
Patient knowledge was evaluated by questionnaires before and 6 
months after the education; anticoagulation stability was evaluated 
by the international normalized ratio (INR) in the 6-month periods 
before and after the intervention.
Results: Six months after the intervention, the educated patients had 
better safety-relevant knowledge and their anticoagulation tended to 
be more stable than before the education. Knowledge and INR stabil-
ity did not change in the controls. In particular, 68% of the patients 
knew that acetaminophen (paracetamol) is the safest over-the-counter 
analgesic for the combination with phenprocoumon compared with 
22% before (P < 0.001). Basic diet rules were known to 71% of the 
patients compared with 30% before (P < 0.001). Painful swelling 
realized 60% as a signal symptom compared with 26% before (P < 
0.001). Suddenly disturbed speech was a signal symptom to 80% 
compared with 49% of these patients before the education (P < 
0.001). How to proceed after a forgotten intake knew 57% compared 
with 14% before the education (P < 0.001). The INR was outside 
the intended range for 29% of the time during the 6 months after 
the education in the intervention group compared with 36% of the 
time in the control patients (P = 0.09).
Conclusion: Self-empowering patients with this 1-hour education 
significantly improved patient knowledge over 6 months and tended 
to improve the intermediate end point INR stability. This education 
could be easily implemented in routine practice. In addition, this 
education provides a promising example to self-empower patients 
in further therapies.
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Introduction: Acenocoumarol is a vitamin K antagonist charac-
terized by a large interpatient variability in the dose required to 
achieve target anticoagulation. There is extensive evidence that a 
large part of the variability of VKAs can be explained by genetic 
factors, especially polymorphisms in the VKORC1 and the CYP2C9 
genes. The objective of this study was to investigate the impact of 
CYP2C9 polymorphisms and drug−drug interactions on the risk of 
overanticoagulation and on the mean daily dose in patients treated 
with acenocoumarol.
Patients (or Materials) and Methods: This prospective observational 
study included 115 hospitalized patients starting acenocoumarol treat-
ment. Data were collected during the first 35 days of therapy and included 
sex, age, INR measurements, acenocoumarol doses, comorbidities, and 
comedications. Patients were genotyped for CYP2C9, CYP2C19, and 
VKORC1. Drugs known to inhibit CYP2C9 using the table developed 
by the Division of Clinical Pharmacology and Toxicology, Geneva 
University Hospitals, Switzerland, were carefully listed.
Results: The difference for time to overanticoagulation in pres-
ence or absence of CYP2C9 inhibitors for all patients, independ-
ent of the genotype, was significant (P < 0.001). The presence of 
a CYP2C9 inhibitor or a CYP2C9 polymorphism, independently, 
statistically increased the risk of overanticoagulation (HR = 2.8 [P < 
0.001] and HR = 1.7 [P = 0.004], respectively). For CYP2C9*1/*1 
genotype only, in the presence of a CYP2C9 inhibitor, 52% of 
wild-type patients presented an INR ≥ 4 versus 22% in absence of 
a CYP2C9 inhibitor. In wild-type patients, the HR was 2.7 (P = 
0.02) in the presence of a CYP2C9 inhibitor compared with the 
absence of CYP2C9 inhibitor. For patients carriers of CYP2C9*2 or 
CYP2C9*3 alleles, in the presence of a CYP2C9 inhibitor, 78% of 
carriers presented an INR ≥ 4 versus 48% in the absence of CYP2C9 
inhibitor. For patients carriers of CYP2C9*2 or CYP2C9*3 alleles, 
the HR was 2.9 (P = 0.01) in presence of a CYP2C9 inhibitor. 
Presence of the CYP2C9*3 allele and VKORC1-1639GA and 
VKORC1-1639AA were significantly associated with a lower dose 
compared with wild-type subjects with a decrease of nearly 35%, 
25%, and 45%, respectively, in dose requirement. CYP2C9*2 and 
CYP2C19*2 were not associated with lower acenocoumarol doses. 
The presence of a CYP2C9 inhibitor was associated with a decrease 
of 20% in dose requirement (P < 0.05).
Conclusion: The results of our study confirm that the presence of at 
least 1 allelic variant of CYP2C9 and/or the prescription of CYP2C9 
inhibitors expose patients to an increased additive risk of overanti-
coagulation. The VKORC1-1639GA and -1639AA genotypes and 
the presence of a CYP2C9*3 allele were associated with a lower dose 
of acenocoumarol. These findings support that CYP2C9 genotyping 
could be useful for identifying patients requiring a closer monitoring, 
especially in the presence of a CYP2C9 inhibitor.
Disclosure of Interest: None declared.
OC037—Sleep QualiTy Of ChrONiC 
beNzODiazepiNe uSerS iN NurSiNg hOmeS:  
a COmparaTiVe STuDy wiTh NON-uSerS
J. Bourgeois1*; M. Elseviers2; L. Van Bortel1; M. Petrovic3; and  
R. Vander Stichele1
1Heymans Institute of Pharmacology, Ghent University, Ghent; 
Oral Communications Abstracts
2013 e15
2Department of Nursing Science, University of Antwerp, Antwerp; 
and 3Department of Geriatrics, Ghent University Hospital, Ghent, 
Belgium
Introduction: Benzodiazepines and z-drugs (BZD/Zs) are the most 
commonly prescribed symptomatic treatment for sleep problems. 
Older persons, and more specifically the nursing home residents, 
are large consumers of these drugs (> 30% of the Belgian nursing 
home residents take BZD/Z chronically for insomnia). Chronic use 
of BZD/Z is discouraged because of the unproven long-time effective-
ness and the related side effects. The objective of this study was to 
describe sleep quality of chronic BZD/Z users and compare it with 
nonhypnotic users.
Patients (or Materials) and Methods: All mentally competent 
residents from 10 nursing homes were screened and compiled in a 
group of chronic BZDs users or in a group of nonusers, based on 
the medication chart. We collected demographic, functional, and 
medication characteristics, and global and specific sleep parameters, 
using the Pittsburgh Sleep Quality Index (PSQI). Linear regression 
was used to investigate which parameters were associated with sleep 
quality.
Results: Of the 300 residents, 178 (59%) were chronic BZD users 
and 122 nonusers. The 2 groups did not differ in demographic and 
functional characteristics (mean age, 85.5 years; range, 57−100 
years; 75% women). The users reported significantly more diffi-
culties with falling asleep, more midnight awakenings, were less 
rested in the morning, and had a worse self-perceived sleep qual-
ity compared with nonusers. Sleep duration and time to fall asleep 
did not differ. The self-perceived sleep quality was mainly deter-
mined by problems during initiation of sleep. After controlling for 
demographic, medication, and functional characteristics, BZD use 
remained strongly associated with bad sleep (r = 0.173, P = 0.003), 
and a study center effect (differences among nursing homes) was 
observed (r = 0.229, P < 0.001).
Conclusion: Our findings do not support long-term effectiveness of 
BZDs; chronic users slept worse than nonusers (even more outspo-
ken in users of long-acting BZDs). In future longitudinal compara-
tive studies of sleep quality, unexplained variability needs further 
assessment with medical, psychological, and institutional param-
eters.
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Introduction: The use of antipsychotics is highly prevalent in resi-
dential care, often used off-label for Behavioural and Psychological 
Symptoms of Dementia (BPSD). Nowadays, atypical or second-
generation antipsychotics have replaced the majority of older antip-
sychotics. We wanted to explore the indications and dosages of 
antipsychotics used by nursing home residents, focusing on atypical 
antipsychotics.
Patients (or Materials) and Methods: Medication charts of 1730 
residents from 76 nursing homes in Belgium (2006) were collected 
and analyzed, using the ATC classification. Drug name, indication, 
and daily dosage were recorded. We compared the Prescribed Daily 
Dose (PDD) with the Defined Daily Dose (DDD) for atypical antip-
sychotics based on the WHO ATC/DDD index.
Results: Nursing home residents used in 32.9% antipsychot-
ics of which 19.1% atypical and 16.1% typical antipsychotics. 
Concomitant use of ≥ 2 antipsychotic medications was found in 5% 
of the cases. Risperidone and olanzapine were the main used atypical 
antipsychotics (13.5% and 5.5%, respectively). Buterophynone deri-
vates (12.1%) were the main used typical antipsychotics, of which 
haloperidol accounted for 5%. The main indications for prescribing 
antipsychotics were agitation within dementia (57%), and psychosis 
(23%). The median PDD for risperidone was 0.5 mg (range, 0.25−9 
mg), lower than the recommended DDD (5 mg); 15 mg for aripipra-
zole, equal to the recommended DDD; 5 mg (range, 1.25–25) for 
olanzapine, lower than recommended DDD (10 mg); 100 mg (range, 
25−400 mg) for quetiapine, also lower than recommended (400 mg).
Conclusion: The DDD for antipsychotics is based on the main indi-
cation of psychosis. In Belgian nursing homes, antipsychotics are 
mainly used off-label for BPSD. The PDD of antipsychotics for nurs-
ing home residents is systematically lower than the DDD (except for 
aripiprazole), indicating that GPs do take the altered drug disposition 
of the aging body as well as the off-label indication of BPSD into 
consideration.
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